PharmaEssentia
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING0
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +17.6 months). See all sponsors →
Open PharmaEssentia on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Ropeginterferon alfa-2b NCT05485948 |
P2 | Active, not recruiting | Polycythemia Vera | 49 | 2022-09-07 |
| SURPASS ET NCT04285086 |
P3 | Active, not recruiting | Essential Thrombocythemia | 174 | 2024-11-12 (+33 mo) |
| Ropeginterferon alfa-2b-njft (P1101) NCT05482971 |
P2 | Active, not recruiting | Essential Thrombocythemia | 91 | 2025-05-09 (+9 mo) |
| P1101 (Ropeginterferon alfa-2b-njft) NCT05481151 |
P3 | Active, not recruiting | Polycythemia Vera | 111 | 2025-06-30 (+18 mo) |
| Ropeginterferon alfa-2b NCT06468033 |
P3 | Active, not recruiting | Primary Myelofibrosis; Myeloproliferative Neoplasm | 160 | 2027-11-18 (+18 mo) |